Entact Bio Revenue and Competitors

Location

#9946

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Entact Bio's estimated annual revenue is currently $3.5M per year.(i)
  • Entact Bio's estimated revenue per employee is $77,500
  • Entact Bio's total funding is $121M.

Employee Data

  • Entact Bio has 45 Employees.(i)
  • Entact Bio grew their employee count by 36% last year.

Entact Bio's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
FounderReveal Email/Phone
3
SVP, Biological SciencesReveal Email/Phone
4
Executive Director, Molecular DiscoveryReveal Email/Phone
5
Director, Data ScienceReveal Email/Phone
6
DirectorReveal Email/Phone
7
Associate DirectorReveal Email/Phone
8
Director, Biophysics & BiochemistryReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
Associate Principal ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Entact Bio?

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

keywords:N/A

$121M

Total Funding

45

Number of Employees

$3.5M

Revenue (est)

36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9M457%N/A
#2
$9M450%N/A
#3
$9.7M450%N/A
#4
$9.3M460%N/A
#5
$12.1M462%N/A